Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia David DingliAyalew Tefferi OriginalPaper Pages: 69 - 74
The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective Martha WadleighD. Gary Gilliland OriginalPaper Pages: 75 - 80
A refined diagnostic algorithm for polycythemia vera that incorporates mutation screening for JAK2V617F Ayalew Tefferi OriginalPaper Pages: 81 - 86
Is it justified to perform a bone marrow biopsy examination in sustained erythrocytosis? Juergen ThieleHans Michael Kvasnicka OriginalPaper Pages: 87 - 92
Targeting the c-kit receptor in the treatment of acute myelogenous leukemia Anjali S. Advani OriginalPaper Pages: 101 - 107
Chemotherapy for patients with acute myeloid leukemia in first remission Kenneth Bradstock OriginalPaper Pages: 108 - 113
Clinical implications of gene expression profiling of acute myeloid leukemia Kenneth I. MillsAmanda F. Gilkes OriginalPaper Pages: 114 - 121
Is cytarabine required in the treatment of acute promyelocytic leukemia? Lionel AdèsPierre Fenaux OriginalPaper Pages: 122 - 125
Gene arrays in lymphoma: Where will they fit in? Javeed IqbalFrancesco d’AmoreKai Fu OriginalPaper Pages: 129 - 136
